Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious disease efforts.

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US federal district courts, aligning with recent Delaware law changes, while the ...

The stock has rapidly outpaced the broader market, but the long-term implications of the hantavirus are unclear.

Presented by Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Moderna’s mRNA flu shot to get FDA review After some initial ...

Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...

AFP / Moderna shares are surging after a report the drugmaker confirmed it's working on a potential hantavirus vaccine. Several people have tested positive for the rare hantavirus on the cruise ship ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - The hantavirus outbreak on the MV Hondius poses an ‘extremely low’ overall risk to the public, health official ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against emerging infectious diseases,” the Cambridge-based company said.

The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new ...